TW201507725A - 羥基多甲氧基黃酮類化合物及/或其衍生物之用途 - Google Patents
羥基多甲氧基黃酮類化合物及/或其衍生物之用途 Download PDFInfo
- Publication number
- TW201507725A TW201507725A TW102129499A TW102129499A TW201507725A TW 201507725 A TW201507725 A TW 201507725A TW 102129499 A TW102129499 A TW 102129499A TW 102129499 A TW102129499 A TW 102129499A TW 201507725 A TW201507725 A TW 201507725A
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- mice
- fat
- day
- preadipocytes
- Prior art date
Links
- 125000002887 hydroxy group Chemical group [H]O* 0.000 title claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 241000207199 Citrus Species 0.000 claims abstract description 12
- 208000008589 Obesity Diseases 0.000 claims abstract description 12
- 235000020824 obesity Nutrition 0.000 claims abstract description 12
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 10
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 8
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 8
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 229930003935 flavonoid Natural products 0.000 claims description 41
- 235000017173 flavonoids Nutrition 0.000 claims description 41
- 150000002215 flavonoids Chemical class 0.000 claims description 38
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 235000005979 Citrus limon Nutrition 0.000 claims description 6
- 244000131522 Citrus pyriformis Species 0.000 claims description 6
- 241001672694 Citrus reticulata Species 0.000 claims description 6
- 240000000560 Citrus x paradisi Species 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 150000002632 lipids Chemical class 0.000 abstract description 3
- 235000020971 citrus fruits Nutrition 0.000 abstract description 2
- 230000011759 adipose tissue development Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 54
- 210000000229 preadipocyte Anatomy 0.000 description 54
- 239000003925 fat Substances 0.000 description 39
- 230000004069 differentiation Effects 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 20
- 239000002609 medium Substances 0.000 description 19
- 102000001253 Protein Kinase Human genes 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 17
- 108060006633 protein kinase Proteins 0.000 description 17
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 16
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 210000001789 adipocyte Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 210000002149 gonad Anatomy 0.000 description 13
- 210000001015 abdomen Anatomy 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 8
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 8
- 102000038030 PI3Ks Human genes 0.000 description 8
- 108091007960 PI3Ks Proteins 0.000 description 8
- 108010016731 PPAR gamma Proteins 0.000 description 8
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 8
- 229960005489 paracetamol Drugs 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 230000035508 accumulation Effects 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000000411 inducer Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 210000000579 abdominal fat Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 230000022131 cell cycle Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- -1 troches Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 4
- 230000018199 S phase Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 3
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 102000010970 Connexin Human genes 0.000 description 3
- 108050001175 Connexin Proteins 0.000 description 3
- 230000035519 G0 Phase Effects 0.000 description 3
- 230000010190 G1 phase Effects 0.000 description 3
- 230000004668 G2/M phase Effects 0.000 description 3
- 102000008078 Sterol Regulatory Element Binding Protein 1 Human genes 0.000 description 3
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 3
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 3
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000002710 gonadal effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000006372 lipid accumulation Effects 0.000 description 3
- 230000004132 lipogenesis Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 238000013116 obese mouse model Methods 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 2
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010018763 Biotin carboxylase Proteins 0.000 description 2
- 210000003771 C cell Anatomy 0.000 description 2
- 101710186200 CCAAT/enhancer-binding protein Proteins 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100023915 Insulin Human genes 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000012130 whole-cell lysate Substances 0.000 description 2
- 230000007730 Akt signaling Effects 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100026748 Fatty acid-binding protein, intestinal Human genes 0.000 description 1
- 108050008832 Fatty acid-binding protein, intestinal Proteins 0.000 description 1
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 235000010674 Prunella vulgaris Nutrition 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003520 lipogenic effect Effects 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本發明所揭羥基多甲氧基黃酮類化合物之用途係有關於抑制脂肪生成、抑制脂肪分化及降低脂肪累積,因而羥基多甲氧基黃酮類化合物係得以一預定劑量而作為一抑制肥胖或治療脂肪肝之醫藥組合物內之有效成份,亦或得作為一食品之組成份,其中,該羥基多甲氧基黃酮類化合物係來自於一柑橘屬植物之果皮。
Description
本發明係有關於天然化合物之用途,特別係指一種羥基多甲氧基類黃酮類之用途。
按,肥胖發生之主要原因係在於個體攝取之熱量高於其所消耗之熱量,使過多能量以三酸甘油脂之型態累積於脂肪組織中,進而堆積於胰臟、肝臟、骨骼肌等處,促使肥胖及代謝症候群(metabolic syndrome)之產生,如心血管疾病、高血壓、高血脂症、第二型糖尿病等。目前世界衛生組織係將肥胖列為一種慢性疾病,而台灣2004~2008年之營養健康調查結果乃顯示營養過剩之結果會導致許多慢性疾病之發生。
肥胖之治療方法眾多,如透過運動、控制熱量、外科手術等方式,惟,現代人工作繁忙,且飲食習慣皆以外食為主,因而欲以運動及控制熱量等手段減重皆無法有良好效果,另以如抽脂手術、胃繞道手術等外科手術之手段減重,其所需花費較高,並且術中會對於個體造成不確定風險。另有透過藥物,如代謝刺激劑、食慾抑制劑、澱粉阻斷劑等,達到減重之功效,然而長期服用藥物仍有可能對於人體造成副作用。而為了避免服用藥物可能對人體健康產生之潛在不良影響,目前有許多研究係揭露天然成份或天然萃取物得藉由抑制食慾、增加能量代謝等機制,達到抑制
肥胖之功效,如咖啡因抑制磷酸二脂酶(phosphodiesterase)而提高細胞內環腺苷酸(cyclic adenosine monophosphate)以增加能量之代謝、蝴蝶亞仙人掌萃取物得抑制食慾、夏枯草萃取物得抑制唾液澱粉酶之活性而作為澱粉阻斷劑、仙連素或車前子係得促進脂質代謝而降低血液中三酸甘油脂。
基於上述天然成份或天然萃取物之作用機制係非直接藉由調節脂肪細胞之生命週期、抑制脂肪細胞分化、促進脂肪細胞分解作用等機制所達成者,因而減肥效果係較為不顯著,是以,為能更有效地抑制脂肪累積及抑制肥胖,目前許多研究乃致力於開發出能夠透過調解脂肪細胞功能或抑制脂肪形成之天然成份。
本發明之主要目的係在於提供一種羥基多甲氧基黃酮類(hydroxyl polymethoxylflavones;HPMFs)化合物及/或其於藥學上能接受之鹽類及/或上述形式以任意比例所形成之組合物之用途,其係用於製備抑制肥胖之藥物,用以抑制個體體內脂肪生成及脂肪分化,並且於不改變攝食率之狀況下,可降低脂肪組織於臟器之累積,其中,該羥基多甲氧基黃酮類化合物係來自一柑橘屬植物之果皮,而該柑橘屬植物係得為柚、柑、橘、橙或檸檬等。
本發明之另一目的係在於提供一種羥基多甲氧基黃酮類(hydroxyl polymethoxylflavones;HPMFs)化合物及/或其於藥學上能接受之鹽類及/或上述形式以任意比例所形成之組合物之用途,其係用於製備治療脂肪肝之藥物,用以改善脂肪肝病變,並且減少於肝臟中所累積油滴,
其中,該羥基多甲氧基黃酮類化合物係來自一柑橘屬植物之果皮,而該柑橘屬植物係得為柚、柑、橘、橙或檸檬等。
本發明之次一目的係在於提供一種食品,其係用以提供作為個體於日常預防代謝症候群或相關症狀之用,而該食品係至少包含一羥基多甲氧基黃酮類化合物,其中,該羥基多甲氧基黃酮類化合物係來自一柑橘屬植物之果皮,而該柑橘屬植物係得為柚、柑、橘、橙或檸檬等。
第一圖A係為3T3-L1前脂肪細胞培養第0天之細胞型態。
第一圖B係為3T3-L1前脂肪細胞培養第2天之細胞型態。
第一圖C係為3T3-L1前脂肪細胞培養第4天之細胞型態。
第一圖D係為3T3-L1前脂肪細胞培養第6天之細胞型態。
第一圖E係為3T3-L1前脂肪細胞培養第8天之細胞型態。
第一圖F係為3T3-L1前脂肪細胞培養第8天以油紅O染色之結果。
第二圖A及B係分別為經不同處理之3T3-L1前脂肪細胞於分化第8天以油紅O染色之結果。
第二圖C係表示經不同處理之3T3-L1前脂肪細胞於分化第8天時,其三酸甘油脂之含量。
第三圖A係表示經不同處理之3T3-L1前脂肪細胞於分化第8天時,其PPARγ之表現。
第三圖B係表示經不同處理之3T3-L1前脂肪細胞於分化第8天時,其之C/EBPα之表現。
第四圖A係表示經不同處理之3T3-L1前脂肪細胞於分化第8天時,其脂肪酸合成酶表現。
第四圖B係表示經不同處理之3T3-L1前脂肪細胞於分化第8天時,其之脂肪酸連結蛋白2表現。
第四圖C係表示經不同處理之3T3-L1前脂肪細胞於分化第8天時,其乙醯輔脢A羧化酶表現。
第五圖A係表示經不同處理之3T3-L1前脂肪細胞於分化第8天時,其腺苷酸活化蛋白激酶α及磷酸化腺苷酸活化蛋白激酶α上Thr172之表現。
第五圖B係表示經不同處理之3T3-L1前脂肪細胞於分化第8天時,其腺苷酸活化蛋白激酶β及磷酸化腺苷酸活化蛋白激酶β上Ser108之表現。
第五圖C係表示經不同處理之3T3-L1前脂肪細胞於分化第8天時,其固醇調節元件結合蛋白1c之表現。
第六圖係表示經不同處理之3T3-L1前脂肪細胞於分化第8天時,其PI3K及磷酸化PI3K上Tyr508與AKT及磷酸化AKT上之Ser473之表現。
第七圖係為經不同處理之3T3-L1前脂肪細胞之細胞週期分析之結果。
第八圖係為經不同條件飼養之各組小鼠之體重變化。
第九圖係為經不同條件飼養之各組小鼠之攝食量。
第十圖係為經不同條件飼養之各組小鼠之外觀。
第十一圖A至D係分別為經不同條件飼養之各組小鼠之性腺脂肪外觀。
第十二圖A至D依序分別為經不同條件飼養之小鼠之腹部脂肪外觀。
第十三圖係為經不同條件飼養之各組小鼠之性腺脂肪重量。
第十四圖係為經不同條件飼養之各組小鼠之腹部脂肪重量。
第十五圖係為經不同條件飼養之各組小鼠之腸道脂肪重量。
第十六圖A至D依序分別為經不同條件飼養之各組小鼠之肝臟切片染色圖。
本發明所揭羥基多甲氧基黃酮類化合物及/或其衍生物之用途係有關於抑制脂肪生成、抑制脂肪分化及降低脂肪累積,而該羥基多甲氧基黃酮類化合物及/或其衍生物係得以一有效劑量而作為製備用於抑制肥胖或治療脂肪肝之藥物之有效成份,亦得用於製備一食品組成物,其中,該羥基多甲氧基黃酮類化合物係來自於一柑橘屬植物之果皮。藉由對一個體投予該藥物或該食品組成物,用以抑制該個體體內脂肪細胞分化以及降低脂肪細胞累積。
更進一步而言,該羥基多甲氧基黃酮類化合物乃係將多甲氧基黃酮類(polymethoxylflavones;PMFs)上之至少一甲氧基(-OCH3)
轉變為氫氧基(-OH)而得者。
過去研究中係指出3T3-L1前脂肪細胞分化為成熟脂肪細胞係係涉及許多因子之作用,如透過刺激脂質生合成相關之轉錄因子,如PPAR及C/EBPs,則能促進3T3-L1前脂肪細胞分化,其中,C/EBPs係能活化脂肪代謝酵素的基因,如脂肪酸連結蛋白2(fatty acid binding protein 2;aP2);固醇調節元件結合蛋白(SREBP-1)係為脂肪分化之決定因子,能用以轉錄出許多重要之脂肪生成基因,如脂肪酸合成酶(fatty acid synthase;FAS)、乙醯輔脢A羧化酶(acetyl-CoA carboxylase;ACC),而能加速合成脂肪酸及脂肪,更得用以活化PPARγ。此外,透過LKB1/STK11會磷酸化腺苷酸活化蛋白激酶α(AMPK α)上之Thr172而使之活化,進而磷酸化乙醯輔脢A羧化酶活性降低,抑制脂肪酸合成,換言之,調節腺苷酸活化蛋白激酶(Adenosine monophosphate-activated protein kinase;AMPK),因而其係成為抗脂肪生成之指標。
由於本發明所揭之羥基多甲氧基黃酮類化合物係調節脂肪分化之轉錄因子及相關路徑,因而能夠具有抑至脂肪分化及減緩脂肪成熟知能力,詳言之,該羥基多甲氧基黃酮類化合物係能夠抑制脂肪細胞分化過程中重要之轉錄因子表現,如PPARγ及C/EBPα,並且抑制下游目標基因之蛋白質表現,如乙醯輔脢A羧化酶、脂肪酸合成酶、aP2,而能減緩三酸甘油酯之累積,再者,其係能活化腺苷酸活化蛋白激酶之訊息傳遞路徑及抑制PI3K/Akt之訊息傳遞路徑,而能達到抑制前脂肪細胞分化之目的。
而本發明說明書與申請專利範圍中所揭名詞係分別說明如下,惟,下列說明僅為例示性說明,非作為限制本發明說明書及申請專利
範圍者。
所謂「藥物」,係指由一有效成份,如本發明所揭羥基多甲氧基黃酮類化合物、其於藥學上能接受之鹽類或上述形式以任意比例所形成之組合物,與至少一醫藥上可接受載體及/或賦形劑結合而製成適當投予形式,其中,適當投予形式係如粒劑、粉劑、錠劑、膠囊劑、栓劑、汁液、懸浮劑、滴劑、可用以注射之溶劑等。
所謂「藥學上可接受之鹽類」,係指羥基多甲氧基黃酮類化合物之酸性或鹼性產物,而得呈其鹽類或游離形式存在,其中,可形成鹽之羥基多甲氧基黃酮類化合物,係包含其立體異構物形式者。
所謂「有效劑量」,係指依據個體種類、個體重量及投予方式進行計算後所得。
所謂「投予」,係指口服、吸入、經直腸內、經皮膚吸收、或藉由皮下、動脈、靜脈、腹膜等注射方式。
所謂「食品」,係指以任何形式存在而得供個體食用者,如粒狀製品、粉狀製品、固體、液態製品、懸浮液製品、半固態製品、乳品等食品。
以下將茲舉若干實例及圖式作更進一步說明如后。
實例一:製備羥基多甲氧基黃酮類化合物
取10公克橘皮萃取物,其內含有40%多甲氧基黃酮類,以95%之乙醇溶解後再加入3M之鹽酸(hydrochloric acid;HCl)。將上述混合溶液進行加熱迴流12小時,其反應過程皆以TLC和LC/MS監測,待反應結束後冷卻,並以真空裝置去除乙醇,加入乙酸乙酯和水進行萃取。收集
有機層萃取物,水層萃取物後再以乙酸乙酯萃取後合併。完成合併之有機萃取層以稀釋之碳酸氫鈉(sodium bicarbonate)溶液、水及鹽水(30% NaCl)溶液洗滌,並且以無水硫酸鈉(sodium sulfate)去除水分予以乾燥。而後經由過濾、減壓濃縮與凍乾(lyophilized)後所得到呈淡黃色固體係為羥基多甲氧基黃酮類化合物。
實例二:3T3-L1前脂肪細胞培養
將3T3-L1前脂肪細胞培養以含10%小牛血清,10,000 units/mL盤尼西林與10,000μg/mL鏈黴素之DMEM培養基中,於10公分培養盤中,置於5%二氧化碳之37℃細胞培養箱中進行培養。當細胞生長至約7~8分滿時,去除培養液並以磷酸鹽緩衝液沖洗後,於37℃加入適量胰蛋白酶(trypsin-EDTA)後,輕拍培養盤使所培養出之細胞脫離培養盤底部,再以新鮮之培養基終止胰蛋白酶之作用,利用吸量管抽吸數次將細胞均勻打散後,以固定比例將細胞均勻分配至各種大小之培養盤中,置於5%二氧化碳之37℃細胞培養箱中培養。
實例三:3T3-L1前脂肪細胞分化試驗
將3T3-L1前脂肪細胞種入24孔培養盤中,以一含有小牛血清(fetal calf serum)之DMEM培養基培養3天後,再將培養基換成另一含有小牛血清(fetal bovine serum)之DMEM培養基培養2天而將此培養完成日定義為第0天,並得依據不同處理條件於第2天加入DMI誘導劑(DEX、MIX、insulin)培養基培養2天,用以使3T3-L1前脂肪細胞分化。再將培養基換成一含10%小牛血清(fetal bovine serum)及5μg/mL藥劑INS之DMEM培養基,培養2天後,於第4天、第6天及第8天時分別將培養基換成
一含有10%小牛血清(fetal bovine serum)之培養基。而於第0天至第8天之培養過程中每2天觀察3T3-L1前脂肪細胞之細胞型態,結果如第一圖A至E所示,並將完成第8天培養之3T3-L1前脂肪細胞以油紅O染色,結果如第一圖F所示,其中,紅色部份係為脂肪細胞內之紅色脂肪球。
由第一圖之結果顯示未分化之3T3-L1前脂肪細胞之細胞型態係紡錘狀(如第一圖A);而於第2天時,部份3T3-L1前脂肪細胞之細胞型態逐漸變為圓形;於第4天時,3T3-L1前脂肪細胞內始產生小型油滴;於第6天時,3T3-L1前脂肪細胞內所聚集之油滴增加;而於第8天時,90%以上之3T3-L1前脂肪細胞係分化為成熟之脂肪細胞,其內有大小油滴聚集。
實例四:3T3-L1前脂肪細胞內脂質堆積試驗
如同實例三之步驟進行3T3-L1前脂肪細胞之分化至第8天,並且於分化過程中以不同處理條件予以分為四組,其中,第一組係為空白組,第二組係為僅於第2天加入DMI培養基者,作為對照組,第三組與第四組則分別於第2天加入DMI培養基,並分別於培養第0天、第2天、第4天、第6天添加劑量為10μg/mL及20μg/mL之羥基多甲氧基黃酮類化合物。將各組於8天培養完成,將細胞進行染色(Oil Red O),並以顯微鏡觀察並拍照,結果如第二圖A及B所示。再以分光光度計(510nm)進行定量,結果如第二圖C所示。
由第二圖之結果顯示,未加入DMI誘導劑之第一組,其3T3-L1前脂肪細胞係為未分化之狀態,細胞型態呈現紡錘狀;僅以DMI誘導劑處理之第二組,其3T3-L1前脂肪細胞細分化成為成熟之脂肪細胞,細胞型態係呈圓形,並且可觀察到成熟之脂肪細胞內所具有紅色脂肪球;而
第三組及第四組所得之3T3-L1前脂肪細胞內紅色脂肪球分別相較第二組乃減少許多。換言之,羥基多甲氧基黃酮類化合物乃可抑制經DMI誘導劑誘導3T3-L1前脂肪細胞脂質合成作用。是以,由第二圖結果顯示,以羥基多甲氧基黃酮類化合物處理後,3T3-L1前脂肪細胞內脂質含量有減少之趨勢,並且得顯著性抑制前脂肪細胞內脂質堆積。
實例五:羥基多甲氧基黃酮類化合物抑制脂肪分化之機制分析
如同實例三及實例四之步驟將3T3-L1前脂肪細胞進行分化培養至第8天,並於分化過程中以不同處理條件而予以分為四組,其中,第一組係為空白組,第二組係為僅於第2天加入DMI培養基者,作為對照組,第三組與第四組則分別於第2天加入DMI培養基,並分別於培養第0天、第2天、第4天、第6天添加劑量為10μg/mL及20μg/mL之羥基多甲氧基黃酮類化合物。收集各組之全細胞溶解液,以西方點墨法進行各組之蛋白質表現之分析,結果如第三圖至第五圖所示,其中,第三圖A係為各組PPARγ之表現,第三圖B係為各組C/EBPα之表現,第四圖A係為各組之脂肪酸合成酶表現結果,第四圖B係為各組脂肪酸連結蛋白2之表現,第四圖C係為各組乙醯輔脢A羧化酶之表現;第五圖A係為各組腺苷酸活化蛋白激酶α及磷酸化腺苷酸活化蛋白激酶α上Thr172(p-AMPKα(Thr172))之表現,第五圖B係為各組腺苷酸活化蛋白激酶β及磷酸化腺苷酸活化蛋白激酶β上Ser108(p-AMPK(Ser108))之表現,第五圖C係為各組之固醇調節元件結合蛋白1c(SREBP-1c)表現。
另如同上述步驟而分為三組,係為空白組,第二組係為僅於
第2天加入DMI培養基者,作為對照組,第三組係於第2天加入DMI培養基,並於培養第0天、第2天、第4天、第6天添加劑量為20μg/mL之羥基多甲氧基黃酮類化合物。而後收集各組之全細胞溶解液,以西方點墨法進行各組之蛋白質表現之分析,結果如第六圖所示,其中,第六圖係為各組PI3K及磷酸化PI3K上Tyr508(p-PI3K(Tyr508))與AKT及磷酸化AKT上之Ser473(p-Akt(Ser473))之表現。
由第三圖及第四圖之結果可知僅以DMI誘導劑處理之第二組,其PPARγ、C/EBPα、乙醯輔脢A羧化酶、脂肪酸合成酶及aP2等蛋白質之表現量皆較第一組增加,而以羥基多甲氧基黃酮類化合物處理之第三組或第四組,其PPARγ、C/EBPα、乙醯輔脢A羧化酶、脂肪酸合成酶及脂肪酸連結蛋白2等蛋白質之表現量係較第二組之表現量下降。由第五圖之結果可知磷酸化腺苷酸活化蛋白激酶α上Thr172與磷酸化腺苷酸活化蛋白激酶β上Ser108之表現量於第一組與第二組中係無差異,而相較於第二組,第三組或第四組中磷酸化腺苷酸活化蛋白激酶α上Thr172與磷酸化腺苷酸活化蛋白激酶β上Ser108之表現量係隨著羥基多甲氧基黃酮類化合物之濃度增加而上升,並減少固醇調節元件結合蛋白1c之表現量。由第六圖之結果可知第二組之磷酸化PI3K上Tyr508及磷酸化AKT上之Ser473之表現係較第一組者為增加,而第三組中磷酸化PI3K上Tyr508及磷酸化AKT上之Ser473之表現則較第二組減少。
由第三圖至第六圖之結果顯示由於羥基多甲氧基黃酮類化合物得抑制脂肪細胞分化過程中所必須之轉錄因子PPARγ、C/EBPα及下游蛋白質乙醯輔脢A羧化酶、脂肪酸合成酶及aP2之表現,並增加磷酸化腺苷
酸活化蛋白激酶α及腺苷酸活化蛋白激酶β上之蛋白質而活化腺苷酸活化蛋白激酶訊息傳遞路徑,減少固醇調節元件結合蛋白表現量而抑制PPARγ基因表現及下游蛋白質乙醯輔脢A羧化酶和脂肪酸合成酶表現,且減少磷酸化PI3K上Tyr508及磷酸化AKT上之Ser473而抑制PI3K/Akt訊息傳遞路徑,據此,可達到抑制3T3-L1前脂肪細胞分化之功效。
實例六:3T3-L1前脂肪細胞之細胞週期分析
將3T3-L1前脂肪細胞種入24孔盤中,以一含有小牛血清(fetal calf serum)之DMEM培養基培養3天,再將培養基換成另一含有小牛血清(fetal bovine serum)之DMEM培養基培養2天後,將此培養完成日定義為第0天,而後依據不同培養條件予以分組,培養2天,其中,第一組係為空白組,第二組係為僅於第2天加入DMI培養基者,作為對照組,第三組與第四組則分別於第2天加入DMI培養基,並分別添加劑量為10μg/mL及20μg/mL之羥基多甲氧基黃酮類化合物。於18及24小時,分別將各組細胞固定而以碘化丙啶染色,藉由流式細胞儀及軟體(ModFit LT)分析各組之細胞週期分佈,結果如第七圖及下表一所示。
由第七圖之結果可知於處理18小時後,第一組係有76.72%之3T3-L1前脂肪細胞停滯於G0/G1期,僅由15.36%之3T3-L1前脂肪細胞進入S期,第二組係有71.89%之3T3-L1前脂肪細胞進入S期,第三組係29.64%之3T3-L1前脂肪細胞進入S期,第四組係有12.21%之3T3-L1前脂肪細胞進入S期;而處理24小時後,第一組3T3-L1前脂肪細胞之細胞週期仍停滯於G0/G1期,第二組之3T3-L1前脂肪細胞係有35.47%進入G2/M期,第三組係有10.17%之3T3-L1前脂肪細胞進入G2/M期,第四組之3T3-L1前脂肪細胞僅有4.84%進入G2/M期。由第七圖結果顯示DMI誘導劑乃會誘發3T3-L1前脂肪細胞之細胞擴增(mitotic clonal expansion),而羥基多甲氧基黃酮類化合物係得延緩經DMI誘導劑所誘發之細胞擴增現象,使細胞週期停滯在G0/G1期,影響3T3-L1前脂肪細胞分化而抑制脂肪生成。
實例七:製備肥胖小鼠動物模式
取預定數量之週齡4週C57BL/6雄性小黑鼠,分為四組而分別以不同飼養條件對待,其中,第一組係為空白組,僅餵食飼料及水,第二組係餵食膏油脂飼料及水,第三組係餵食高油脂飼料、水及劑量為每公斤250毫克之羥基多甲氧基黃酮類化合物,第四組係餵食高油脂飼料、水及劑量為每公斤10克之羥基多甲氧基黃酮類化合物。各組小鼠係飼養10週,每週分別測量各組小鼠之重量,如第八圖所示,而各組小鼠之攝食量經統計係如第九圖所示,並且於第十週時拍攝各組小鼠之外觀,分別如第十圖A至D所示。
由第八圖至第十圖之結果可知於第0週至第10週之飼養過程中,各組小鼠所攝取之飼料量差異性不大;而於體重變化方面,第一組
小鼠體重由20.27克增加至23.91克,增加15.18克,第二組小鼠體重由19.93克增加至35.11克,增加15.18克,第三組小鼠體重由19.15克增加至27.18克,增加8.03克,第四組小鼠體重由19.32克增加至27.18克,增加7.86克;而經由10週飼養,第二組之小鼠外觀相較於第一組之小鼠外觀係明顯變大,第三組及第四組之小鼠外觀分別較第二組小之鼠外觀變小,且第四組之小鼠外觀更相近第一組之小鼠外觀。據此,由上述結果顯示餵食高油脂飼料確實可製備肥胖小鼠,而藉由餵食羥基多甲氧基黃酮類化合物,可抑制肥胖小鼠之體重增加。換言之,羥基多甲氧基黃酮類化合物係具有抑制體重增加之功效。
實例八:各組小鼠之各臟器重量分析
將實例七之各組小鼠予以犧牲,並分別將各組小鼠之肝臟、腎臟、脾臟稱重後紀錄結果如下表二所示。
由表二之結果可知相較於第一組小鼠,第二組小鼠之肝臟及腎臟重量分別增加0.33克及0.06克,顯示多餘脂肪係累積於臟器內而使臟器重量增加,而相較於第二組小鼠,第三組小鼠之肝臟及腎臟重量分別減少0.17克及0.10克,第四組小鼠之肝臟及腎臟重量分別減少0.24克及0.14克,顯示餵食羥基多甲氧基黃酮類化合物具有抑制脂質累積於肝臟及腎臟等臟
器之功效,並且隨著餵食劑量增加,其效果更為顯著。再者,由於第一組至第四組之小鼠脾臟重量皆無顯著差異性存在,顯示羥基多甲氧基黃酮類化合物不具有毒性。
實例九:各組小鼠體內脂肪分析
將實例七之各組小鼠予以犧牲後,分別取各組小鼠之性腺、腹部、腸道之白色脂肪組織而觀察各該部位之脂肪組織外觀,結果如第十一圖及第十二圖所示,其中,第十一圖A至D依序分別為第一組至第四組小鼠之性腺脂肪外觀,第十二圖A至D依序分別為第一組至第四組小鼠之腹部脂肪外觀。再者,將各組小鼠之性腺、腹部、腸道之脂肪予以稱重,結果如下:第一組小鼠性腺、腹部、腸道之脂肪重量分別為0.60g、0.06g、0.34g;第二組小鼠性腺、腹部、腸道之脂肪重量分別為1.65g、0.56g、0.67g;第三組小鼠性腺、腹部、腸道之脂肪重量分別為0.79g、0.21g、0.39g;第四組小鼠性腺、腹部、腸道之脂肪重量分別為0.42g、0.06g、0.27g,並將稱重結果經統計後如第十三圖至第十五圖所示,其中第十三圖係為各組小鼠性腺脂肪重量之稱重結果,第十四圖係為各組小鼠腹部脂肪重量之稱重結果,第十五圖係為各組小鼠腸道脂肪重量之稱重結果。
由第十一圖至第十二圖之結果可知相較於第一組之性腺及腹部脂肪外觀,第二組之性腺及腹部脂肪外觀明顯變大;然相較於第二組之性腺及腹部脂肪外觀,第三組及第四組之性腺及腹部脂肪外觀則分別明顯變小。再者,由第十三圖至第十四圖之結果可知相較於第一組小鼠性腺、腹部、腸道之脂肪重量,第二組小鼠性腺、腹部、腸道之脂肪重量分別增加1.05克、0.50克、0.33克;而相較於第二組小鼠性腺、腹部、腸道之脂肪
重量,第三組小鼠性腺、腹部、腸道之脂肪重量分別降低0.86克、0.35克、0.26克,第四組小鼠性腺、腹部、腸道之脂肪重量分別降低1.23克、0.50克、0.38克。由第十一圖至第十五圖之結果顯示羥基多甲氧基黃酮類化合物係具有抑制脂肪組織擴張之功效,並且隨著劑量增加而能增加該功效。
實例十:各組小鼠之血清生化檢測
將實例七之各組小鼠予以犧牲後,分別取各組小鼠血液,經離心後而得到血清,用以進行血清中之天門冬酸轉胺酵素(GOT)、丙胺酸轉胺酵素(GPT)、三酸甘油酯(TG)及總膽固醇(T-cho)等肝臟生化功能指標之分析,結果如下表三所示。
由表三之結果可知第二組小鼠相較於第一組小鼠,其丙胺酸轉胺酵素、三酸甘油酯及總膽固醇之濃度係分別較為上升,而第三組及第四組小鼠分別相較於第一組小鼠,其天門冬酸轉胺酵素、丙胺酸轉胺酵素、三酸甘油酯及總膽固醇則皆分別減少。因此,由表三之結果顯示羥基多甲氧基黃酮類化合物係具有降低脂肪肝病變之風險及降低脂肪累積之功效,並且該功效係得隨著餵食劑量增加而提昇。
實例十一:各組小鼠肝臟切片分析
將實例七之各組小鼠犧牲後而分別取其肝臟,將各組小鼠之
肝臟先以福馬林固定,再以石蠟包埋後進行切片。而後將各組小鼠之肝臟切片進行脫蠟後而以蘇木精-伊紅染劑予以染色,結果如第十六圖所示,其中,第十六圖A至D依序分別為第一組至第四組小鼠肝臟切片染色之結果。
由第十六圖之結果可知相較於第一組之肝臟細胞來說,第二組之肝臟細胞排列有顯著不同,並且其內累積大量油滴而得造成肝臟之病變,而餵食低劑量羥基多甲氧基黃酮類化合物之第三組小鼠肝臟切片中所累積之油滴係較為減少,餵食高劑量羥基多甲氧基黃酮類化合物之第四組小鼠肝臟切片不僅大幅減少其內所累積之油滴,並且使肝臟細胞之排列趨於正常狀態。是以,由第十六圖之結果顯示羥基多甲氧基黃酮類化合物係具有改善脂肪肝病理狀況之功效,並且該功效係得隨著餵食劑量增加而提昇。
據此,藉由本發明所揭羥基多甲氧基黃酮類化合物所具有抑制脂肪分化、抑制脂肪成熟、改善脂肪肝、降低脂肪堆積之能力,而能夠作為一藥物之有效成份,達到抑制肥胖或治療脂肪肝之目的,此外,基於該羥基多甲氧基黃酮類化合物係來自於天然植物之故,對於細胞無毒性,而得降低對個體之副作用,另亦能作為食品組成份而製備成為日常保健食品,達到預防肥胖及改善脂肪肝之目的。
以上僅是藉由各該實施例詳細說明本發明,熟知該技術領域者於不脫離本發明精神下,而對於說明書中之實施例所做的任何簡單修改或是變化,均應為本案申請專利範圍所得涵攝者。
Claims (9)
- 一種羥基多甲氧基黃酮類(hydroxyl polymethoxylflavones;HPMFs)化合物及/或其於藥學上能接受之鹽類及/或上述形式以任意比例所形成之組合物之用途,其係用於製備抑制肥胖之藥物。
- 依據申請專利範圍第1項所述用途,其中,該羥基多甲氧基黃酮類化合物係來自一柑橘屬植物之果皮。
- 依據申請專利範圍第2項所述用途,其中,該柑橘屬植物係選自由柚、柑、橘、橙及檸檬所組成之群。
- 一種羥基多甲氧基黃酮類化合物及/或其於藥學上能接受之鹽類及/或上述形式以任意比例所形成之組合物之用途,其係用於製備治療脂肪肝之藥物。
- 依據申請專利範圍第4項所述用途,其中,該羥基多甲氧基黃酮類化合物係來自一柑橘屬植物之果皮。
- 依據申請專利範圍第5項所述用途,其中,該柑橘屬植物係選自由柚、柑、橘、橙及檸檬所組成之群。
- 一種羥基多甲氧基黃酮類化合物之用途,其係用於製備一食品組成物。
- 依據申請專利範圍第7項所述用途,其中,該羥基多甲氧基黃酮類化合物係來自一柑橘屬植物之果皮。
- 依據申請專利範圍第8項所述用途,其中,該柑橘屬植物係選自由柚、柑、橘、橙及檸檬所組成之群。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW102129499A TWI559919B (en) | 2013-08-16 | 2013-08-16 | The uses of hydroxyl polymethoxylflavones and/or derivative thereof |
KR20140005987A KR20150020001A (ko) | 2013-08-16 | 2014-01-17 | 히드록시기 폴리메톡시플라본 화합물 및 그 유도체를 사용하는 방법 |
US14/165,860 US8946288B1 (en) | 2013-08-16 | 2014-01-28 | Uses of hydroxyl polymethoxylflavones (HPMFs) and derivatives thereof |
KR1020160076498A KR20160094896A (ko) | 2013-08-16 | 2016-06-20 | 히드록시기 폴리메톡시플라본 화합물 및 그 유도체를 사용하는 방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW102129499A TWI559919B (en) | 2013-08-16 | 2013-08-16 | The uses of hydroxyl polymethoxylflavones and/or derivative thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201507725A true TW201507725A (zh) | 2015-03-01 |
TWI559919B TWI559919B (en) | 2016-12-01 |
Family
ID=52395621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW102129499A TWI559919B (en) | 2013-08-16 | 2013-08-16 | The uses of hydroxyl polymethoxylflavones and/or derivative thereof |
Country Status (3)
Country | Link |
---|---|
US (1) | US8946288B1 (zh) |
KR (2) | KR20150020001A (zh) |
TW (1) | TWI559919B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111281863A (zh) * | 2018-12-06 | 2020-06-16 | 大江生医股份有限公司 | 用于减脂的化合物及其应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202017583A (zh) * | 2018-11-05 | 2020-05-16 | 大江生醫股份有限公司 | 柑橘幼果的萃取物及其用途 |
KR102279861B1 (ko) | 2019-04-26 | 2021-07-20 | 박재규 | 청귤류로부터 5-o-디메틸노빌레틴의 추출/분리 및 만성 알코올성 지방간 손상보호 조성물 |
-
2013
- 2013-08-16 TW TW102129499A patent/TWI559919B/zh active
-
2014
- 2014-01-17 KR KR20140005987A patent/KR20150020001A/ko active Search and Examination
- 2014-01-28 US US14/165,860 patent/US8946288B1/en active Active
-
2016
- 2016-06-20 KR KR1020160076498A patent/KR20160094896A/ko active Search and Examination
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111281863A (zh) * | 2018-12-06 | 2020-06-16 | 大江生医股份有限公司 | 用于减脂的化合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
US20150051272A1 (en) | 2015-02-19 |
KR20160094896A (ko) | 2016-08-10 |
TWI559919B (en) | 2016-12-01 |
KR20150020001A (ko) | 2015-02-25 |
US8946288B1 (en) | 2015-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013087023A1 (zh) | 一种天然减肥保健组合物及其应用 | |
TW201507725A (zh) | 羥基多甲氧基黃酮類化合物及/或其衍生物之用途 | |
CN112439018A (zh) | 具有减肥降脂的组合物及其制备方法和应用 | |
CN111956751A (zh) | 一种治疗高尿酸血症的药物组合物及其制备方法 | |
CN101879162A (zh) | 一种α-亚麻酸乙酯配伍小檗碱的减肥物 | |
CN101002857A (zh) | 一种中药组合物及其用途 | |
CN104415135B (zh) | 羟基多甲氧基黄酮类化合物及/或其衍生物的用途 | |
CN101019897B (zh) | 一种抗肿瘤的药物组合物及其制备方法 | |
CN104523925A (zh) | 一种中药组合物及其在解热并促排便方面的应用 | |
CN106727480B (zh) | Fex-3在制备抗肥胖症药物中的应用 | |
CN101904856A (zh) | 1,6-二磷酸果糖及其衍生物在制备动物医疗保健品中的应用 | |
CN102961415B (zh) | 忍冬木层孔菌或其提取物的用途 | |
WO2022178967A1 (zh) | 佛司可林-异佛司可林与五环三萜类化合物的药物组合物及其应用 | |
CN108079217A (zh) | 一种轻身丸 | |
CN103829254A (zh) | 一种原花青素在制备减肥食品或药品中的应用 | |
CN110123824B (zh) | 毛冬青皂苷a1的新用途 | |
CN108619283B (zh) | 一种用于改善脂质代谢、减少内脏脂肪的组合物 | |
CN111544440A (zh) | 地奥司明及组合物在制备抗肥胖的产品方面中的应用 | |
CN110420270A (zh) | 一种含有山茶油和鱼油的功能性组合物及其应用 | |
KR101572311B1 (ko) | 2-아미노-2-노보네인카르복실산을 함유하는 비만 예방 또는 치료용 조성물 | |
CN109200056A (zh) | 聚肌胞在防治胰腺炎及其相关病症中的用途 | |
CN111686239A (zh) | 抗真菌化合物的应用 | |
CN107648482A (zh) | 一种用于治疗神经退行性疾病的中药组合物 | |
CN115252630B (zh) | 黄柏酮在制备预防、改善或治疗非酒精性脂肪肝的药物中的应用 | |
CN112791166B (zh) | 一种增强肌肉性能且缓解运动性疲劳的药食同源组合物 |